Table Of Content

Fowles Author Index Bertrand Y >Capdeville R 385 D Bhaskar NK > Rimoy GH 203 BixlerEO—Vgontzas AN 209 Dahlqvist R, Lange R 1 A Bjorkman S, Carlsson M, BerntorpE 325 Dalton N—Imbimbo BP 421 BlinO > Lacarelle B 477 Dangoumau J— MiremontG 285 Aarbakke J > KlemetsdalB 231 Blondeel L—BeringsD 501 DayerP—CarraraV 29 Aarons L, Balant LP, Mentré F, Morselli PL, BoddE—HagenE 445 De Lepeleire I> Van Hecken A 123 Rowland M, Steimer J-L, VozehS 389 BoisselJ-P—NonyP 191 DeghenghiR—Imbimbo BP 421 AgbedanaEO—AhanekuJE 249 Bonn R-—Cawello W 275 Del Bufalo A—Tonstad$ 405 AgostonS >Broek Lvanden 225 BonnR-—VogtD 319 Dembowski J— Orzechowska-Juzwenko K AguileraL—CalvoR 484 Boo T de > Bartelink ML 557 481 Agusti A, ArnauJM, Laporte J-R 95 Boon NA > Wright RA 279 Dengler HJ >ReichelC 417 AhaJE, nTayleorGOk, Wualke rO, Borbe HO-KirstenR 271 Denneberg T > Carlsson MS 576 AgbedanaEO,SowunmiA,SalakoLA 249 Borg-CostanziJM— Dixon JS 167 Depré M— Van HeckenA 123 Alberti KGMM > Wright RA 279 Borge M—HagenE 445 De Schepper > Van Hecken A 123 Albertioni F, Herngren L, Juliusson G, Botsch S, Heinkele G, Meese CO, Eichelbaum De Sommers K->SnymanJR 19 Liliemark J 563 M, Kroemer HK 133 De Sommers K-> Wyk Mvan 437 Alihanka J, Lahdenpera A, KailaT 507 Bouchaud O >GimenezF 561 De Sommers K, Wyk Mvan,SnymanJR 441, Alkner U +SvenssonC 59 Boulieu R->CombarnousF 379 569 Allen A, Asgill CC, Pierce DM, Upward J, Boutignon F >Imbimbo BP 421 Dibbelt L—LoutonT 77 Zussman BD 159 BreartG—AutretE 197 Dickinson RG > BernusI 473 AlvanG-—JerlingM 67 Breckenridge AM Ng HWK 361 Dietrich B— Holland RL 461 AminD—-Imbimbo BP 421 Breidert M—KirstenR 271 Ding RW, Port RE, Ortmann K, Liebmann B, Andersson P-E—RenelandR 431 Breithaupt K-MeyCde 295 Spahn-Langguth H, Mutschler E, Weber E Andrew M—EggenAE 491 Bremerich D—BehneM 301 455 Aranko K-BackmanJT 551 Breyne Bde >NonyP 191 Dixon JS, Borg-Costanzi JM, Langley SJ, ArauJM—AgustiA 95 Brockmeier D—ReichelC 417 Lacey LF, ToonS 167 ArrigoniL >ConciaE 371 Broek L van den, Wierda JMKH, Proost JH, Djurup R—HvidbergA 15 AsgillCC— Allen A 159 Hommes FDM, AgostonS 225 Dombret MC — Bergogne-BérézinE 87 Aubier M > Bergogne-Bérézin E 87 Brown SN > Rhodes KM 479 Domino EF, Kadoya C, MatsuokaS 527 Aubry A-F >GimenezF 561 BrunoA, CarucciP, CassaM,d Caevarllo - Durand A —Lacarelle B 477 Audebert C >Lacarelle B 477 Perin P,GrudenG, OlivettiC,PaganoG 411 DurgeatS— Mignot A 383 Auquier P—>Lacarelle B 477 DutertreJP— AutretE 83 Autret E, Breart G, Jonville AP, Courcier S, Lassale C,GoehrsJM 197 Cc Autret E, Jonville AP, Dutertre JP, Bertiere E MC, Robert M, Averous M,Couet W 83 Calvo R, Suarez E, Aguilera L, Rodriguez AverousM— AutretE 83 SasiainJM 484 Eadie MJ >BernusI 473 CandianiC > MiadonnaA 127 Ebihara A—SudohT 267 Capdeville R, Mousson B, Bax G, Bertrand Y, Eckernis S-A-—>GrahnénA 143 B Philippe N 385 Eckrich B > Volz-ZangC 399 Carlsson M > Bjérkman§ 325 Edwards M—Imbimbo BP 421 Backman JT, Aranko K, Himberg J-J, Olkkola Carlsson MS, Denneberg T, Emanuelsson Eggen AE, AndrewM 491 KT 551 B-M, Kagedal B, LindgrenS 576 Ehrsson H, Wallin I, Ros AM, Eksborg S, Berg Bailleul F >BertinP 3 Carrara V, Porchet H, Dayer P 29 M 375 Balant LP AaronsL 389 CarucciP—>BrunoA 411 Eichelbaum M—BotschS 133 Baldo-EnziG — Zambon§ 221 Cassader M—BrunoA 411 EksborgS —EhrssonH 375 Barbhaiya RH. Shukla UA, Pfeffer M, Cavallo-PerinP—BrunoA 411 E] Desoky E-Gramatté T 253 Pittman KA, Shrotriya R, Laroudie C, CawelloW —KnaufH 9 Emanuelsson B-M > Carlsson MS_ 576 GammansRE 41 Cawello W, Schweer H, Miiller R, Bonn R, Encarnacion M, ChinI 533 BardJM—HagenE 445 SeyberthHW 275 EnlundH >NiskanenL 101 Bartelink ML, Wollersheim H, Vemer H, Chang FY,ChenF,LeeSD 91 ErdegB—KirstenR 271 Thomas CMG, Boo T de, Thien T 557 ChenF—ChangFY 91 Eriksen H-M—HagenE 445 BartucciF >ConciaE 371 Chetty M, Miller R, MoodleySV 523 Eriksson JW, Fowelin J, Urbanavicius V BascoLK—GimenezF 561 ChiandussiL > VeglioF 119 469 Bax G—Capdeville R 385 ChinI > EncarnacionM 533 Erkelens DW > TonstadS 405 Beaulac-Baillargeon L,RocheleauS 451 Chossegros P—>Combarnous F 379 Bégaud B—MiremontG 285 Clark GA Newnham DM 511 Behne M, Bremerich D, Heinrich J, Claus M— WolterK 179 F Schumacher H,SchererM 301 Combarnous F, Fouque D, Bernard N, Belz GG —MeyCde 295 Boulieu R, Chossegros P, Laville M, Zech P Falkenhausen M von—ReichelC 417 Berg M—EhrssonH 375 379 FarehS—NonyP 191 Bergogne-Bérézin E, Muller-Serieys C, Concia E, Cruciani M, Bartucci F, Arrigoni L, FarinottiR ~GimenezF 561 Aubier M, Dombret MC 87 LongoniA 371 FerroniMA -PacificiGM 49 Berings D, Blondeel L, HabrakenH 501 CortellaA—Zambon$ 221 Fleishaker JC, Hulst LK 35 Bernard N->Combarnous F 379 CottiniM—MiadonnaA 127 Fliser D> Neubeck M 537 Berntorp E> Bjérkman$ 325 Couet W—> AutretE 83 Fliser D > ZwettlerU 185 Bernus I, Dickinson RG, Hooper WD, Eadie Couraud L— Mignot A 383 Fliser M—Neubeck M 537 MJ 473 CourcierS— AutretE 197 Fouque D->CombarnousF 379 Bertiere MC AutretE 83 CrepaldiG— ZambonS 221 Fowelin J > ErikssonJW 469 Bertin P, Lapicque F, Payan E, Rigaud M, CrucianiM—ConciaE 371 Fowles SE, Pratt SK, Laroche J, Prince WT Bailleul F, Jaeger S, Treves R, NetterP 3 Currie D— McDevitt DG 23 355 Fritschka Fritschka E> Wolter K 179 J Laroche J—>FowlesSE 355 Fruchart JC HagenE 445 Laroudie C—BarbhaiyaRH 41 Fujimura A—>SudohT 267 Jackson SHD >GainsboroughN 163 LassaleC— AutretE 197 JaegerS—BertinP 3 LaufenH—ZimmermannT 147 Jahn P > Volz-ZangC 399 Laville M—>Combarnous F 379 G JaéhnchenE—RufG 545 Le Bras J >GimenezF 561 JahnchenE—VogtD 319 Leaver N— Tsang VT 261 Gainsborough N, Nelson ML, Maskrey V, Jensen JD, Jensen LW, Madsen JK 333 LeeSD—ChangFY 91 Swift CG, JacksonSHD 163 Jensen LW—JensenJD 333 Leeuwenkamp OR, Visscher HW, Mensink Gammans RE > BarbhaiyaRH 41 Jerling M, AlvanG 67 CK,JonkmanJHG 243 GaoHY,LiWanPoA 71 Jibikil, YamaguchiN, MomonoiF 367 Leizorovicz ANonyP 191 GeraS—>RufG 545 JohanssonG —GrahnénA 143 Lenaerts V—Imbimbo BP 421 GillotinC —GimenezF 561 Johnston A Tsang VT 261 Li Wan Po A—GaoHY 71 Gimenez F, Gillotin C, Basco LK, Bouchaud Jonkman JHG > Leeuwenkamp OR Li Wan Po A— Zhang WY 517 O, Aubry A-F, Wainer IW, Le Bras J, 243 Liebmann B— Ding RW 455 FarinottiR 561 Jonville AP— AutretE 83,197 Lievre M—NonyP 191 GirreC > RochdiM 351 Jormanainen V >NiskanenL 101 Liliemark J > AlbertioniF 563 Giuliani L > PacificiGM 49 Joubert M— Mignot A 383 Lindgren S Carlsson MS 576 Giverhaug T > KlemetsdalB 231 Juliusson G > AlbertioniF 563 Lipworth BJ >Newnham DM 511 GoehrsJM—AutretE 197 LithellHRenelandR 431 Golay A Tonstad$ 405 Lizamore DJ >SnymanJR 19 Gordin A—KeranenT 151 K LofflerK > RufG 545 Gozdzik A — Orzechowska-Juzwenko K 481 LongoniA—ConciaE 371 Grahnén A, Olsson B, Johansson G, Eckernas KadoyaC Domino EF 527 Louton T, Kuhnz W, Dibbelt L, Knuppen R S-A 143 Kagedal B-> Carlsson MS 576 77 Gramatté T, El Desoky E, Klotz U 253 KailaT—AlihankaJ 507 Léwenhielm CGP > MalmvikJ 291 GrudenG—BrunoA 411 Kaila T, Roivas L, Neuvonen PJ 237 LuusHG-—RufG 545 Gucci A > PacificiGM 49 Kales A Vgontzas AN 209 Kallio A > Kivist6 KT 345 Kamali F, ThomasSHL 565 M H KarloécaiK > TomesanyiJ 173 KarlssonM —KeranenT 151 MacGregor IR Wright RA 279 HabrakenH—BeringsD 501 Karonen S-L > Mattila MJ 215 MadsenJK —-JensenJD 333 Hagen E, Istad H, Ose L, Bodd E, Eriksen Karsenty H > Lacarelle B 477 Malmvik J, Lowenhielm CGP, Melander A H-M, Selvig V, Bard JM, Fruchart JC, Borge Kaufmann J > Krause W 339 291 M, Wolf M-C, Pfister P 445 Keller U + Miserez AR 107 Mant T—Imbimbo BP 421 HaenniA—RenelandR 431 Kerdanen T, Gordin A, Karlsson M, Korpela K, ManzatoE—ZambonS$ 221 HaradaK—SudohT 267 Pentikainen PJ, Rita H, Schultz E, Seppala Maskrey V >GainsboroughN 163 HaramburuF + MiremontG 285 L, WikbergT 151 Matsuoka S ~ Domino EF 527 Hasegawa T, Takagi K, Nadai M, Ogura Y, Kirsten R, Breidert M, Nelson K, Heine A, Mattila MJ, VanakoskiJ, Mattila-Evenden NabeshimaT 55 Rosenkranz S, Erdeg B, Niebch G, Borbe ME, KaronenS-L 215 Haugh MC>NonyP 191 HO, Siebert-Weigel M, Respondek J 271 Mattila-Evenden ME > Mattila MJ 215 Heine A KirstenR 271 Kivist6 KT, Kallio A, Neuvonen PJ 345 McDevitt DG ~Newnham DM 511 HeinkeleG—BotschS 133 Klemetsdal B, Straume B, Giverhaug T, McDevitt DG, Currie D, Nicholson AN, HeinrichJ >BehneM 301 AarbakkeJ 231 Wright NA, Zetlein MB 23 Heritier F Tsang VT 261 Klotz U>GramattéT 253 McFarlane LC > Newnham DM 511 Herngren L— AlbertioniF 563 Knauf H, Cawello W, Schmidt G, Mutschler E Meese CO BotschS 133 Hilsted J> Hvidberg A 15 9 Melander A > MalmvikJ 291 Himberg J-J > Backman JT 551 Knuppen R—LoutonT 77 Melander A—MerloJ 393 HimbergJ- J > LaaksonenR 313 KochHJ 573 MelchioR— VeglioF 119 Hodson ME > Tsang VT 261 Konishi H, Morita K, Yamaji A 309 Mensink CK ~ Leeuwenkamp OR 243 Hoffmann A > Merkel U 175 KorpelaK —KeranenT 151 Mentré F> AaronsL 389 Holland RL, Wesnes K, DietrichB 461 Krause W, Schuhmann-Giampieri G, Staks T, Merkel U, Sigusch H, Hoffmann A 175 Hommes FDM > Broek Lvanden 225 KaufmannJ 339 Merlo J, Ranstam J, Rastam L, Wessling A, Hooper WD > BernusI 473 Kroemer HK >BotschS 133 MelanderA 393 Hora Z > Orzechowska-Juzwenko K Kubota K, Inman WHW 497 Mey C de, Breithaupt K, Seibert-Grafe M, 481 Kuhnz W > LoutonT 77 BelzGG 295 Horriere F > Lacarelle B 477 Miadonna A, Cottini M, Candiani C, Tedeschi Hulst LK >FleishakerJC 35 A 127 Hvidberg A, Djurup R, HilstedJ 15 L Mignot A, Millerioux L, Couraud L, Durgeat S,Joubert M 383 Laaksonen R, Ojala J-P, Tikkanen MJ, Milejski P > Orzechowska-JuzwenkoK 481 HimbergJ-J 313 Miller R->ChettyM 523 Lacarelle B, Blin O, Audebert C, Auquier P, Millerioux L— Mignot A 383 Imbimbo BP, Mant T, Edwards M, Amin D, Karsenty H, Horriere F, Durand A 477 Miremont G, Haramburu F, Bégaud B, Péré Dalton N, Boutignon F, Lenaerts V, Lacey LF >DixonJS 167 JC,DangoumauJ 285 Wiithrich P, DeghenghiR 421 Lahdenperé A —AlihankaJ 507 Miserez AR, Ross RA, Keller U 107 Inman W, Pearce G, WiltonL 115 Lahiri A Sridhara BS 427 MoccettiT —TonstadS 405 Inman WHW -> Kubota K 497 Lange RDahlqvistR 1 MomonoiF — Jibikil 367 Istad H-HagenE 445 Langley SJ >DixonJS 167 Moodley SV Chetty M 523 Lapicque F >BertinP 3 Morelli MC > PacificiGM 49 Laporte J-R—AgustiA 95 Morita K > KonishiH 309 Uusitupa Morita K, Yamaji A 137 PearceG—InmanW 115 SchulzW—RufG 545 MorselliPL— AaronsL 389 Pentikadinen PJ >KerainenT 151 Schumacher H +BehneM 301 Mousson B > Capdeville R 385 Péré JC MiremontG 285 SchwartzJ I Van HeckenA 123 Muller-Serieys C > Bergogne-Bérézin E Perrie AM—WrightRA 279 Schweer H > CawelloW 275 87 Persson CGA > SvenssonC 59 Seibert-Grafe M—»>MeyCde 295 Miiller R->CawelloW 275 PfaffG— ZimmermannT 147 Selvig V-—HagenE 445 MutschlerE— Ding RW 455 Pfeffer M— BarbhaiyaRH 41 Seppala L—KerainenT 151 MutschlerE—KnaufH 9 Pfister P—> HagenE 445 Seyberth HW > Cawello W 275 Mutschler E—Neubeck M 537 Philippe N > Capdeville R 385 Shiga T-—SudohT 267 Myers DC Vgontzas AN 209 Pierce DM—AllenA 159 Shrotriya R->BarbhaiyaRH 41 Pipkorn U >SvenssonC 59 Shukla UA > BarbhaiyaRH 41 Pittman KA > BarbhaiyaRH 41 Siebert-Weigel M— Kirsten R 271 N PomettaD ->TonstadS 405 Sigusch H Merkel U 175 Porchet H Carrara V 29 Sj6str6m PA 575 Nabeshima T > Hasegawa T 55 Port RE—DingRW 455 Snyman JR—SommersK De 441,569 NadaiM—HasegawaT 55 Pratt SK — FowlesSE 355 SnymanJR—WykMvan 437 Nelson K > KirstenR 271 Prince WT > Fowles SE 355 Snyman JR, De Sommers K, Wyk M van, Nelson ML—GainsboroughN 163 Pritsch M—Neubeck M 537 Lizamore DJ 19 NetterP—BertinP 3 Proost JH > Broek Lvanden 225 Sowunmi A —AhanekuJE 249 Neubeck M, Fliser D, Pritsch M, WeiBer K, Spahn-Langguth H Ding RW 455 Fliser M, Nussberger J, Ritz E, Mutschler E Sridhara BS, Thomas P, Lahiri A, Raftery EB 537 R 427 Neuvonen PJ > KailaT 237 Staks T-— Krause W 339 Neuvonen PJ > Kivist6 KT 345 Rabbia F > VeglioF 119 Stappaerts I, Van Schil L, Van der Veken J Newnham DM, Wheeldon NM, McFarlane Raftery EB >Sridhara BS 427 305 LC, Clark GA, McDevitt DG, Lipworth BJ RanstamJ—MerloJ 393 Steimer J-L— AaronsL 389 511 RastamL—MerloJ 393 Stenhouse F > Wright RA 279 Ng HWK, Walley TJ, Tsao Y, Breckenridge Reichel C, Falkenhausen M von, Brockmeier Straume B > KlemetsdalB 231 AM 361 D,DenglerHJ 417 SudrezE—CalvoR 484 NgJ— Van HeckenA 123 ReitsmaJ—TonstadS 405 Sudoh T, Fujimura A, Shiga T, Sasaki M, Nicholson AN McDevitt DG 23 Reneland R, Andersson P-E, Haenni A, Harada K, Tateishi T, Ohashi K, Ebihara A Niebch G > KirstenR 271 LithellH 431 267 Niewinski P — Orzechowska-Juzwenko K Respondek J > Kirsten R 271 Svensson C, Alkner U, Pipkorn U, Persson 481 ReyNdela—RufG 545 CGA 59 Niskanen L, Enlund H, Jormanainen V, Rhodes KM, BrownSN 479 Swiebodzki L — Orzechowska-Juzwenko K Nissinen A, UusitupaM 101 Riemersma RA > Wright RA 279 481 Nissinen A—NiskanenL 101 RigaudM-—BertinP 3 Swift CG + GainsboroughN 163 Nony P, Boissel J-P, Lievre M, Leizorovicz A, Rimoy GH, Wright DM, Bhaskar NK, Rubin Haugh MC, FarehS, Breyne Bde 191 PC 203 NowickiM > ZwettlerU 185 RitaH —>KeranenT 151 T Nussberger J > Neubeck M 537 Ritz E—NeubeckM 537 Ritz E—ZwettlerU 185 Takagi K > HasegawaT 55 Robert M—>AutretE 83 TateishiT ~SudohT 267 oO Rochdi M, Sabouraud A, Girre C, Venet R, TaylorGO—AhanekuJE 249 ScherrmannJM 351 Tedeschi A MiadonnaA 127 Ogbuokiri JE, Ozumba BC, Okonkwo PO Rocheleau S > Beaulac-BaillargeonL 451 Temellini A > PacificiGM 49 89 Rodriguez SasiainJM—CalvoR 484 Thien T > Bartelink ML 557 Ogura Y — HasegawaT 55 Rogstad B 487 Thomas CMG —> Bartelink ML 557 OhashiK —SudohT 267 Roivas L— KailaT 237 Thomas P —Sridhara BS 427 Ojala J-P ~LaaksonenR 313 Ros AM—>EhrssonH 375 Thomas SHL > KamaliF 565 Okonkwo PO > Ogbuokiri JE 89 RosenkranzS—KirstenR 271 Tikkanen MJ >LaaksonenR 313 OlivettiC—BrunoA 411 Ross RA —Miserez AR 107 Tjandramaga TB > Van Hecken A 123 Olkkola KT > Backman JT 551 Rowland M— AaronsL 389 TomesanyiJ, KarlécaiK 173 Olsson B-—GrahnénA 143 Rubin PC Rimoy GH 203 Tonstad S, Pometta D, Erkelens DW, Ose L, Ortmann K— Ding RW 455 Ruf G, Gera S, Luus HG, Trenk D, Rey N de Moccetti T, Schouten JA, Golay A, Reitsma Orzechowska-Juzwenko K, Pawlik J, la, Loffler K, Schulz W, JahnchenE 545 J, Del Bufalo A, Pasotti E, Wal P van der Niewinski P, Milejski P, Dembowski J, Turek 405 J, Gozdzik A, SwiebodzkiL,HoraZ 481 Toon S$ —DixonJS 167 Ose L—HagenE 445 S Trenk D—RufG 545 Ose L—TonstadS 405 Trenk D> VogtD 319 Ozumba BC > OgbuokiriJE 89 Sabouraud A—RochdiM 351 TrevesR—BertinP 3 Salako LA —AhanekuJE 249 Tsang VT, Johnston A, Heritier F, Leaver N, SartoreG—ZambonS 221 Hodson ME, YacoubM 261 P SasakiM—SudohT 267 Tsao YNgHWK 361 SchererM—BehneM 301 Turek J ->Orzechowska-JuzwenkoK 481 Pacifici GM, Ferroni MA, Temellini A, Gucci Scherrmann JM —RochdiM 351 A, Morelli MC, GiulianiL 49 Schmidt G—KnaufH 9 PaganoG—BrunoA 411 Schneidrowski B > Volz-ZangC 399 U Palm D > Volz-ZangC 399 SchoutenJA—TonstadS 405 PasottiE—TonstadS 405 Schuhmann-GiampieriG > Krause W 339 UpwardJ—AllenA 159 Pawlik J ~ Orzechowska-JuzwenkoK 481 Schulte B > Volz-ZangC 399 Urbanavicius V > ErikssonJW 469 PayanE-—BertinP 3 Schultz E—KeranenT 151 Uusitupa M > NiskanenL 101 Van der Veken Vv WalkerO—AhanekuJE 249 Wyk M van, De Sommers K, Snyman JR Walley TJ >NgHWK 361 437 Van der Veken J > StappaertsI 305 WallinI —EhrssonH 375 Van Hecken A, Depré M, SchwartJzI , Weber E—DingRW 455 Tjandramaga TB, Winchell GA, De WeiBer K >Neubeck M 537 Y Lepeleire I, Ng, De Schepper PJ J 123 Wesnes K—>HollandRL 461 Van Schil L > StappaertsI 305 Wessling A—MerloJ 393 YacoubM > Tsang VT 261 Vanakoski J — Mattila MJ 215 Wheeldon NM—>NewnhamDM 511 Yamaguchi N > Jibikil 367 Veglio F, Rabbia F, Melchio R, Chiandussi L Wierda JMKH —> Broek L van den Yamaji A—KonishiH 309 119 WikbergT—KeranenT 151 Yamaji A MoritaK 137 Vemer H - Bartelink ML 557 Wildfeuer A— ZimmermannT 147 YeatesRA—ZimmermannT 147 Venet R-RochdiM 351 WiltonL—InmanW 115 Vgontzas AN, Kales A, Bixler EO, Myers DC Winchell GA > Van Hecken A 123 209 Wolf M-C-—>HagenE 445 Z Visscher HW + Leeuwenkamp OR 243 Wollersheim H > Bartelink ML Vogt D, Trenk D, Bonn R,J ahnchenE 319 557 Zambon §, Cortella A, Sartore G, Baldo-Enzi Volz-Zang C, Eckrich B,J ahn P, Wolter K, Claus M, FritschkaE 179 G, ManzatoE,CrepaldiG 221 Schneidrowski B, Schulte B, Palm D 399 Wright DM > Rimoy GH_ 203 Zech P >CombarnousF 379 VozehS$— AaronsL 389 Wright NA >McDevittDG 23 Zetlein MB >McDevittDG 23 Wright RA, Perrie AM, Stenhouse F, Alberti Zhang WY, LiWanPoA 517 KGMM, Riemersma RA, MacGregor IR, Zimmermann T, Yeates RA, Laufen H, Pfaff Ww BoonNA 279 G, Wildfeuer A 147 Wiithrich P—Imbimbo BP 421 Zussman BD > AllenA 159 Wainer IW >GimenezF 561 WykMvan—SnymanJR 19 Zwettler U, Fliser D, Nowicki M, Ritz E WalP vander—TonstadS 405 WykM van—SommersK De 441,569 185 Doxycycline Subject Index Budesonide; liver, man, sulphotransferase, testosterone, drug me- tabolism 49 (S = Supplement) Buspirone; pharmacokinetics, renal impairment, hepatic impair- ment, healthy volunteers 41 Cc The key words given at the end of the summary of each article have been classified as primary and Candidiasis, Fluconazole; prescription-event, monitoring, safety in secondary key words separated by a semicolon. In pregnancy 115 the index the primary key words are listed alphabeti- Capsaicin, Cough, Captopril; glycopyrrolate 437 cally; the individual primary key words are permuted Capsaicin, Diabetic neuropathy; pain relief, patients 517 in such way that each of them appears in first place Captopril, Capsaicin, Cough; glycopyrrolate 437 once. The secondary key words follow the primary Captopril, Central effects, Atenolol; short term administration, healthy volunteers 23 ones without permutation. Cefotiam, Tissue distribution; cephalosporin, lung tissue 383 Central effects, Atenolol, Captopril; short term administration, healthy volunteers 23 Cetirizine; cutaneous hypersensitivity reaction, eosinophil re- A sponse, grass pollen allergy, blister fluid 19 2-Chloro-2’-deoxyadenosine (CdA), Protein binding, Cladribine; pharmacokinetics, leukaemia 563 ACE Inhibition, Renal failure, Perindoprilat; potassium, extra- Chlorpromazine, Schizophrenic patients; population pharmacoki- renal disposal, renal excretion, hyperkalaemia 185 netics, clearance, cigarette smoking, cannabis smoking 523 Acetaminophen, Ibuprofen, Fever; children, infections disease, ad- Ciclotropium; heart rate, pharmacokinetic/pharmacodynamic verse effects 197 modelling, effect compartment 455 Adverse drug reaction, Prescription-event monitoring; post- Cimetidine, Gastric ulcer, Helicobacter pylori; smoking 91 marketing surveillance, terminology 497 Cladribine, 2-Chloro-2’-deoxyadenosine (CdA), Protein binding; Adverse drug reaction; causality assessment, agreement 285 pharmacokinetics, leukaemia 563 Allergic rhinitis, N-acetyl-aspartyl-glutamate; histamine, leuko- Clotiazepam, Schizophrenia; benzodiazepine derivative, auditory triene C,, nasal challenge 127 hallucinations 367 Allopurinol, Famciclovir, Herpes; pharmacokinetics interaction, Codeine, Drug-prescription; combination analgesics, pharmaco- xanthine oxidase 355 epidemiology, sex-factor, aged 491 Alprazolam, Psychomotor performance, Fluvoxamine; metabolic Coenzyme Q, Ubiquinonen; lovastatin, simvastatin, long-term inhibition, sedation, drug interaction, serotonin reuptake inhibi- treatment 313 tor, benzodiazepine 35 Colchicine; pharmacokinetics, healthy volunteers, elderly subjects, Amiloride, Insulin sensitivity; hyperinsulinaemic euglycaemic absolute bioavailability 351 clamp, glucose utilization, glucose production, healthy volun- teers 469 Combined hyperlipidaemia, Pravastatin; LDL, cholesterol, trigly- Amlodipine, Hypertension; blood pressure, blood biochemistry, cerides, adverse effects, LDL size 221 COMT, Genetic polymorphism; pharmacogenetics, ethnic varia- haematology, Africans 249 tion, Norway, Saami people 231 Amoxycillin, Flucloxacillin, Digoxin; penicillin V, penicillin anti- Congestive heart failure, Theophylline; periodic breathing, adeno- biotics 479 sine 173 Antidepressants, Suicide; risk differences, amitriptyline, lofepra- Cough, Captopril, Capsaicin; glycopyrrolate 437 mine, trimipramine 291 Coumarin, Flavonoids, Grapefruit juice; pharmacokinetics, cyto- Anti-emetic, Granisetron; pharmacokinetics, tolerance, ascending chrome P450, metabolism inhibition 175 dose, healthy subjects 159 Cyciosporin, Cystic fibrosis; pharmacokinetics 261 Arithmetic mean, Standard deviation; pharmacokinetics 573 Cyclosporine A; uptake, human erythrocytes, HPLC 417 Asthma, Pemirolast; theophylline, drug interaction, pharmacoki- Cystic fibrosis, Cyclosporin; pharmacokinetics 261 netics 55 Atenolol, Captopril, Central effects; short term administration, healthy volunteers 23 a,-Acid glycoprotein, Epilepsy; anticonvulsant, carbamazepine, D phenytoin, phenobarbital, valproate, y-glutamyl transpeptidase, Depression, Serotonin; central 5-hydroxytryptamine, fluoxetine, enzyme induction, seizure control 137 f,-Adrenoceptor antagonist, Esmolol; tricresylphosphate, phar- dexfenfluramine, prolactin release 441 Dexmedetomidine; transdermal, pharmacokinetics, «-adrenocep- macokinetics, effect kinetics 399 tor agonist 345 Diabetes mellitus; Type 2 (non-insulin-dependent) diabetes melli- tus, antidiabetic drugs, therapeutic traditions, questionnaire sur- B vey 101 Diabetic neuropathy, Capsaicin; pain relief, patients 517 Bemetizide, Salt excretion pattern; Na*, K*, Cl, Mg”*, Ca*, chron- Diazoxide, Tenoxicam; diastolic pressure, glucose, insulin 569 ic renal failure, renal haemodynamics 9 Digoxin, Amoxycillin, Flucloxacillin; penicillin V, penicillin anti- Benzodiazepines, General Practice; industry-independent drug in- biotics 479 formation, prescribing, intervention, primary care 501 Diltiazem, Hypertension; intra-arterial blood pressure 427 Bioequivalence, Fluocinolone acetonide; drug formulations, vaso- Diltiazem; immediate-release tablet, controlled-release tablet, constrictor activity, topical steroids, tristimulus colour analysis, steady state, pharmacokinetics 243 corticosteroids 71 Dose adjustment, Lisinopril; ACE inhibitors, pharmacokinetics, Bronchodilatation, Oxitropium bromide; nebulised solution, dose- pharmacodynamics, renal failure 537 response study, chronic obstructive pulmonary disease, anti- Doxycycline; bioavailability, pH dependent absorption, pharmaco- cholinergic bronchodilator, adverse effects 305 kinetics, carrageenate, adverse events 143 Vil Drug development Drug development, Population approach; software, pharmaco- G kinetics, pharmacodynamics 389 Drug utilisation, Standardisation; defined daily dose (DDD), car- Ganciclovir, Renal failure; pharmacokinetics, haemodialysis 379 diovascular data, age 393 Gastric ulcer, Helicobacter pylori, Cimetidine; smoking 91 Drug utilization, Myocardial infarction; secondary prevention, B- General Practice, Benzodiazepines; industry-independent drug in- adrenoceptor antagonists, acetylsalicylic acid, calcium channel formation, prescribing, intervention, primary care 501 blockers 95 Genetic polymorphism, COMT; pharmacogenetics, ethnic varia- Drug-prescription, Codeine; combination analgesics, pharmaco- tion, Norway, Saami people 231 epidemiology, sex-factor, aged 491 Glucagon, Hypoglycaemia; intranasal, glucose appearance rate 1 Granisetron, Anti-emetic; pharmacokinetics, tolerance, ascending dose, healthy subjects 159 E Grapefruit juice, Coumarin, Flavonoids; pharmacokinetics, cyto- chrome P450, metabolism inhivition 175 Enantiomers, Malaria, Halofantrine; stereoselectivity, Plasmo- Growth hormone, Hexarelin; growth hormone releasing peptides dium falciparum 561 421 Enoxacin, Theophylline, Fluconazole; cytochrome P-4501 A, drug metabolism, drug interaction 309 Entacapone; catechol-O-methyltransferase; pharmacokinetics; H healthy volunteers, adverse effects, metabolism 151 Enuresis, Oxybutynine chloride; children, pharmacokinetics, ad- Haemophilia B, Factor IX; macromolecules, pharmacokinetics, verse effects, anticholinergic actions 83 methodological study 325 Epanolol, Ischaemic heart disease, Metoprolol; tissue-type plasmi- Halofantrine, Enantiomers, Malaria; stereoselectivity, Plasmo- nogen activator, plasminogen activator inhibitor type 1 279 dium falciparum 561 Epilepsy, a,-Acid glycoprotein; anticonvulsant, carbamazepine, Halothane, Protein binding; drug interaction 484 phenytoin, phenobarbital, valproate, y-glutamy] transpeptidase, Helicobacter pylori, Cimetidine, Gastric ulcer; smoking 91 enzyme induction, seizure control 137 Herpes, Allopurinol, Famciclovir; pharmacokinetics interaction, Erythropoietin; recombinant human erythropoietin, pharmacoki- xanthine oxidase 355 netics, subcutaneous, absorption, bioavailability 333 Hexarelin, Growth hormone; growth hormone releasing peptides Esmolol, 6 ,-Adrenoceptor antagonist; tricresylphosphate, phar- 421 macokinetics, effect kinetics 399 Hoffmann reflex, Tobacco smoking; recovery cycle, plasma nico- Ethinyl estradiol, Trapezoidal rule; variance components, pharma- tine, plasma cotinine 527 cokinetics 77 Hydrocortisone, Methylprednisolone, Insulin resistance; glucose metabolism 411 Hypercholesterolaemia, Fluvastatin; cholestyramine, drug treat- F ment of hypercholesterolaemia, LDL cholesterol, HDL choles- terol, triglycerides, Lp(a), apolipoproteins 445 Factor IX, Haemophilia B; macromolecules, pharmacokinetics, Hypercholesterolaemia, Simvastatin; low density lipoprotein, high methodological study 325 density lipoprotein, triglycerides, HMG-CoA-reductase inhibi- Famciclovir, Herpes, Allopurinol; pharmacokinetics interaction, tors, adverse effects 107 xanthine oxidase 355 Hyperlipidaemia, Orlistat; lipase inhibitor, fat malabsorption, Females, Raynaud’s phenomenon, Skin perfusion; cooling test, cu- LDL cholesterol 405 taneous blood flow, sex hormones, vasospasm 557 Hypertension, Amlodipine; blood pressure, blood biochemistry, Fever, Acetaminophen, Ibuprofen; children, infections disease, ad- haematology, Africans 249 verse effects 197 Hypertension, Diltiazem; intra-arterial blood pressure 427 Flavonoids, Grapefruit juice, Coumarin; pharmacokinetics, cyto- Hypertension, Fosinopril; essential, insulin sensitivity, carry-over chrome P450, metabolism inhibition 175 effect, angiotensin converting enzyme inhibition, atenolol 431 Flosequinan, Xamoterol; pharmacodynamic interactions, healthy Hypertension, Lisinopril, Nifedipine; multicentre study 487 volunteers 361 Hypoglycaemia, Glucagon; intranasal, glucose appearance rate Flucloxacillin, Digoxin, Amoxycillin; penicillin V, penicillin anti- 15 biotics 479 Fluconazole, Candidiasis; prescription-event, monitoring, safety in pregnancy 115 Fluconazole, Enoxacin, Theophylline; cytochrome P-4501 A, drug Ibuprofen, Fever, Acetaminophen; children, infections disease, ad- metabolism, drug interaction 309 verse effects 197 Fluconazole, Itraconazole; pharmacokinetics, food interaction, Infusion, Prostaglandin E,; pharmacokinetics, metabolism, volun- gastric emptying time, pH radiocapsule 147 teers 275 Fluocinolone acetonide, Bioequivalence; drug formulations, vaso- Insomnia, Temazepam; elderly, efficacy, tolerance, intermittent ad- constrictor activity, topical steroids, tristimulus colour analysis, ministration 209 corticosteroids 71 Insulin resistance, Hydrocortisone, Methylprednisolone; glucose Fluvastatin, Hypercholesterolaemia; cholestyramine, drug treat- metabolism 411 ment of hypercholesterolaemia, LDL cholesterol, HDL choles- Insulin sensitivity, Amiloride; hyperinsulinaemic euglycaemic terol, triglycerides, Lp(a), apolipoproteins 445 clamp, glucose utilization, glucose production, healthy volun- Fluvoxamine, Alprazolam, Psychomotor performance; metabolic teers 469 inhibition, sedation, drug interaction, serotonin reuptake inhibi- Intestinal absorption, Ranitidine; intestinal perfusion, second tor, benzodiazepine 35 peak, intestinal water flux, absorption gradient 253 Fosinopril, Hypertension; essential, insulin sensitivity, carry-over Iopromide; X-ray contrast medium, pharmacokinetics, tolerability, effect, angiotensin converting enzyme inhibition, atenolol 431 healthy volunteers, adverse effects 339 Fourier, Isradipine; rhythm, hypertension, diurnal blood pressure rhythm 119 Ischaemic heart disease, Metoprolol, Epanolol; tissue-type plasminogen activator, plasminogen activator inhibitor type1 279 Renal failure Isosorbide dinitrate, Pirsidomine; CAS 936, EDRF, dorsal hand oO vein 295 Isosorbide dinitrate; route of administration, isosorbide-5-mononi- Opiates, Mr 2264 Cl, Respiratory depression; ventilation, mor- trate, finger pulse wave, pharmacokinetics, haemodynamic ef- phine, analgesics, tolerability, adverse events 301 fects, plasma nitrates 319 Opioid antagonist, U-62066E; blood pressure, heart rate, plasma Isradipine, Fourier; rhythm, hypertension, diurnal blood pressure catecholamines, naloxone, Doppler regional blood flow, kappa rhythm 119 receptor 203 Israpidine; haemodynamics, pharmacokinetics, healthy volunteers, Org 7617, Neuromuscular blockade; dose-response relation, time drug input rate 29 course of action, adverse effects, non-depolarizing 225 Itraconazole, Fluconazole; pharmacokinetics, food interaction, Orlistat, Hyperlipidaemia; lipase inhibitor, fat malabsorption, gastric emptying time, pH radiocapsule 147 LDL cholesterol 405 Ivermectin, Breast milk 89 Oxitropium bromide, Bronchodilatation; nebulised solution, dose- response study, chronic obstructive pulmonary disease, anti- cholinergic bronchodilator, adverse effects 305 L Oxybutynine chloride, Enuresis; children, pharmacokinetics, ad- verse effects, anticholinergic actions 83 Lisinopril, Dose adjustment; ACE inhibitors, pharmacokinetics, pharmacodynamics, renal failure 537 P Lisinopril, Nifedipine, Hypertension; multicentre study 487 Paracetamol, Pregnancy; pharmacokinetics 451 Pemirolast, Asthma; theophylline, drug interaction, pharmacoki- M netics 55 Perindoprilat, ACE Inhibition, Renal failure; potassium, extra- Malaria, Halofantrine, Enantiomers; stereoselectivity, Plasmo- renal disposal, renal excretion, hyperkalaemia 185 dium falciparum 561 Phenobarbitone; phenobarbitone-N -glucoside, urine, metabolism Medifoxamine; pharmacokinetics, pharmacodynamics, elderly 473 volunteers 163 Phenytoin, Saliva; therapeutic drug monitoring, pharmacokinetics 5-Methoxypsoralen, Psoriasis; food, pharmacokinetics 375 565 Meropenem, Respiratory infections; bronchial secretions, local Phosphodiesterase inhibitors, Mortality; meta-analysis, chronic concentrations 87 heart failure, vasodilator 191 6-Mercaptopurine, Thiopurine-methyl-transferase; acute lympho- Piretanide, Ramipril; pharmacokinetics, pharmacodynamics, heal- blastic leukaemia; interaction 385 thy volunteers 545 Methylprednisolone, Insulin resistance, Hydrocortisone; glucose Pirsidomine, Isosorbide dinitrate; CAS 936, EDRF, dorsal hand metabolism 411 vein 295 Metoprolol, Epanolol, Ischaemic heart disease; tissue-type plasmi- Plasma exudation, Xanthine derivatives, Nasal airways; fibrinogen, nogen activator, plasminogen activator inhibitor type 1 279 bradykinins, terbutaline, theophylline, nasal mucosa, nasal lav- Metoprolol; bioavailability, bioequivalence, receptor binding as- age, histamine provocation test 59 say, pharmacokinetics, sustained release formulation 237 Population approach, Drug development; software, pharmacoki- Midazolam, Roxithromycin; drug interaction, pharmacokinetics netics, pharmacodynamics 389 551 Pravastatin, Combined hyperlipidaemia; LDL, cholesterol, trigly- Mortality, Phosphodiesterase inhibitors; meta-analysis, chronic cerides, adverse effects, LDL size 221 heart failure, vasodilator 191 Pregnancy, Paracetamol; pharmacokinetics 451 Mr 2264 Cl, Respiratory depression, Opiates; ventilation, mor- Prescription-event monitoring, Adverse drug reaction; postmar- phine, analgesics, tolerability, adverse events 301 keting surveillance, terminology 497 Mucosal oral therapeutic system, Nystatin; candidiasis, nystatin Propafenone, Sparteine; glucuronides, CYP2D6 phenotype 133 salivary concentrations 533 Prostaglandin E,, Infusion; pharmacokinetics, metabolism, volun- Myocardial infarction, Drug utilization; secondary prevention, f- teers 275 adrenoceptor antagonists, acetylsalicylic acid, calcium channel Protein binding, Cladribine, 2-Chloro-2’-deoxyadenosine (CdA); blockers 95 pharmacokinetics, leukaemia 563 Protein binding, Halothane; drug interaction 484 Psoriasis, 5-Methoxypsoralen; food, pharmacokinetics 375 N Psychomotor performance, Fluvoxamine, Alprazolam; metabolic inhibition, sedation, drug interaction, serotonin reuptake inhibi- N-acetyl-aspartyl-glutamate, Allergic rhinitis; histamine, leuko- tor, benzodiazepine 35 triene C,, nasal challenge 127 Psychomotor performance, Suriclone; zopiclone, chlorpromazine Naftopidil, Serotonin; platelets, aggregation 271 interaction, memory, prolactin, adverse effects 215 Naproxen, Synovial fluid, Rheumatoid arthritis; NSAIDs, eicosa- noid, concentration/effect 3 R Nasal airways, Plasma exudation, Xanthine derivatives; fibrinogen, bradykinins, terbuialine, theophylline, nasal mucosa, nasal lav- Ramipril, Piretanide; pharmacokinetics, pharmacodynamics, heal- age, histamine provocation test 59 thy volunteers 545 Neuromuscular blockade, Org 7617; dose-response relation, time Ranitidine, Intestinal absorption; intestinal perfusion, second course of action, adverse effects, non-depolarizing 225 peak, intestinal water flux, absorption gradient 253 Nifedipine, Hypertension, Lisinopril; multicentre study 487 Nortriptyline; dose-dependent kinetics, therapeutic drug monitor- Ranitidine, Renal impairment; pharmacokinetics 167 Raynaud’s phenomenon, Skin perfusion, Females; cooling test, ing 67 cutaneous blood flow, sex hormones, vasospasm 557 Nystatin, Mucosal oral therapeutic system; candidiasis, nystatin salivary concentrations 533 Renal clearance; pharmacokinetics 575 Renal failure, Ganciclovir; pharmacokinetics, haemodialysis 379 Renal failure, Perindoprilat, ACE Inhibition; potassium, extra- renal disposal, renal excretion, hyperkalaemia 185 Renal impairment Renal impairment, Ranitidine; pharmacokinetics 167 T Respiratory depression, Opiates, Mr 2264 Cl; ventilation, mor- phine, analgesics, tolerability, adverse events 301 Teicoplanin; haemodialysis, renal failure, pharmacokinetics 179 Respiratory infections, Meropenem; bronchial secretions, local Temazepam, Insomnia; elderly, efficacy, tolerance, intermittent ad- concentrations 87 ministration 209 Rheumatoid arthritis, Naproxen, Synovial fluid; NSAIDs, eicosa- Tenoxicam, Diazoxide; diastolic pressure, glucose, insulin 569 noid, concentration/effect 3 Testosterone metabolism, Steroid 5a-reductase inhibitor; MK- Roxithromycin, Midazolam; drug interaction, pharmacokinetics 0434, pharmacodynamics, pharmacokinetics 123 551 Theophylline, Congestive heart failure; periodic breathing, adeno- sine 173 Theophylline, Fluconazole, Enoxacin; cytochrome P-4501 A, drug S metabolism, drug interaction 309 Theophylline; flumequine, drug interaction, pharmacokinetics Salbutamol; male, female, 8, -adrenoceptor, menstrual cycle, sys- 477 temic responses 511 Thiopurine-methyl-transferase, 6-Mercaptopurine; acute lympho- Saliva, Phenytoin; therapeutic drug monitoring, pharmacokinetics blastic leukaemia; interaction 385 565 Tissue distribution, Cefotiam; cephalosporin, lung tissue 383 Salmon calcitonin, Skin blister fluid concentration; synthetic, plas- Tobacco smoking, Hoffmann reflex; recovery cycle, plasma nico- ma concentration, pharmacokinetics, adverse effects 371 tine, plasma cotinine 527 Salt excretion pattern, Bemetizide; Na*, K*, Cl, Mg”*, Ca’*, chron- Trapezoidal rule, Ethinyl estradiol; variance components, pharma- ic renal failure, renal haemodynamics 9 cokinetics 77 Schizophrenia, Clotiazepam; benzodiazepine derivative, auditory hallucinations 367 Schizophrenic patients, Chlorpromazine; population pharmacoki- U netics, clearance, cigarette smoking, cannabis smoking 523 Scopolamine, Sleep; transdermal, autonomic nervous activity 507 U-62066E, Opioid antagonist; blood pressure, heart rate, plasma Serotonin, Depression; central 5-hydroxytryptamine, fluoxetine, catecholamines, naloxone, Doppler regional blood flow, kappa dexfenfluramine, prolactin release 441 receptor 203 Serotonin, Naftopidil; platelets, aggregation 271 Ubiquinonen, Coenzyme Q; lovastatin, simvastatin, long-term Simvastatin, Hypercholesterolaemia; low density lipoprotein, high treatment 313 density lipoprotein, triglycerides, HMG-CoA-reductase inhibi- Umespirone; buspirone, EEG, cognitive, neuroendocrine effect tors, adverse effects 107 461 Skin blister fluid concentration, Salmon calcitonin; synthetic, plas- ma concentration, pharmacokinetics, adverse effects 371 Skin perfusion, Females, Raynaud’s phenomenon; cooling test, cu- x taneous blood flow, sex hormones, vasospasm 557 Sleep, Scopolamine; transdermal, autonomic nervous activity 507 Sparteine oxidation polymorphism, Poland 481 Xamoterol, Flosequinan; pharmacodynamic interactions, healthy Sparteine, Propafenone; glucuronides, CYP2D6 phenotype 133 volunteers 361 Standard deviation, Arithmetic mean; pharmacokinetics 573 Xanthine derivatives, Nasal airways, Plasma exudation; fibrinogen, Standardisation, Drug utilisation; defined daily dose (DDD), car- bradykinins, terbutaline, theophylline, nasal mucosa, nasal lav- diovascular data, age 393 age, histamine provocation test 59 Steroid 5a-reductase inhibitor, Testosterone metabolism; MK- 0434, pharmacodynamics, pharmacokinetics 123 Suicide, Antidepressants; risk differences, amitriptyline, lofepra- mine, trimipramine 291 Suriclone, Psychomotor performance; zopiclone, chlorpromazine interaction, memory, prolactin, adverse effects 215 Synovial fluid, Rheumatoid arthritis, Naproxen; NSAIDs, eicosa- noid, concentration/effect 3 >

ebook img

European Journal of Clinical Pharmacology 1994: Vol 46 Index PDF

9 Pages·1994·2.3 MB·English
by  
#periodicals #sim_microfilm #pub_european-journal-of-clinical-pharmacology
Save to my drive
Quick download
Download
Upgrade Premium
Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.

Preview European Journal of Clinical Pharmacology 1994: Vol 46 Index

Fowles Author Index Bertrand Y >Capdeville R 385 D Bhaskar NK > Rimoy GH 203 BixlerEO—Vgontzas AN 209 Dahlqvist R, Lange R 1 A Bjorkman S, Carlsson M, BerntorpE 325 Dalton N—Imbimbo BP 421 BlinO > Lacarelle B 477 Dangoumau J— MiremontG 285 Aarbakke J > KlemetsdalB 231 Blondeel L—BeringsD 501 DayerP—CarraraV 29 Aarons L, Balant LP, Mentré F, Morselli PL, BoddE—HagenE 445 De Lepeleire I> Van Hecken A 123 Rowland M, Steimer J-L, VozehS 389 BoisselJ-P—NonyP 191 DeghenghiR—Imbimbo BP 421 AgbedanaEO—AhanekuJE 249 Bonn R-—Cawello W 275 Del Bufalo A—Tonstad$ 405 AgostonS >Broek Lvanden 225 BonnR-—VogtD 319 Dembowski J— Orzechowska-Juzwenko K AguileraL—CalvoR 484 Boo T de > Bartelink ML 557 481 Agusti A, ArnauJM, Laporte J-R 95 Boon NA > Wright RA 279 Dengler HJ >ReichelC 417 AhaJE, nTayleorGOk, Wualke rO, Borbe HO-KirstenR 271 Denneberg T > Carlsson MS 576 AgbedanaEO,SowunmiA,SalakoLA 249 Borg-CostanziJM— Dixon JS 167 Depré M— Van HeckenA 123 Alberti KGMM > Wright RA 279 Borge M—HagenE 445 De Schepper > Van Hecken A 123 Albertioni F, Herngren L, Juliusson G, Botsch S, Heinkele G, Meese CO, Eichelbaum De Sommers K->SnymanJR 19 Liliemark J 563 M, Kroemer HK 133 De Sommers K-> Wyk Mvan 437 Alihanka J, Lahdenpera A, KailaT 507 Bouchaud O >GimenezF 561 De Sommers K, Wyk Mvan,SnymanJR 441, Alkner U +SvenssonC 59 Boulieu R->CombarnousF 379 569 Allen A, Asgill CC, Pierce DM, Upward J, Boutignon F >Imbimbo BP 421 Dibbelt L—LoutonT 77 Zussman BD 159 BreartG—AutretE 197 Dickinson RG > BernusI 473 AlvanG-—JerlingM 67 Breckenridge AM Ng HWK 361 Dietrich B— Holland RL 461 AminD—-Imbimbo BP 421 Breidert M—KirstenR 271 Ding RW, Port RE, Ortmann K, Liebmann B, Andersson P-E—RenelandR 431 Breithaupt K-MeyCde 295 Spahn-Langguth H, Mutschler E, Weber E Andrew M—EggenAE 491 Bremerich D—BehneM 301 455 Aranko K-BackmanJT 551 Breyne Bde >NonyP 191 Dixon JS, Borg-Costanzi JM, Langley SJ, ArauJM—AgustiA 95 Brockmeier D—ReichelC 417 Lacey LF, ToonS 167 ArrigoniL >ConciaE 371 Broek L van den, Wierda JMKH, Proost JH, Djurup R—HvidbergA 15 AsgillCC— Allen A 159 Hommes FDM, AgostonS 225 Dombret MC — Bergogne-BérézinE 87 Aubier M > Bergogne-Bérézin E 87 Brown SN > Rhodes KM 479 Domino EF, Kadoya C, MatsuokaS 527 Aubry A-F >GimenezF 561 BrunoA, CarucciP, CassaM,d Caevarllo - Durand A —Lacarelle B 477 Audebert C >Lacarelle B 477 Perin P,GrudenG, OlivettiC,PaganoG 411 DurgeatS— Mignot A 383 Auquier P—>Lacarelle B 477 DutertreJP— AutretE 83 Autret E, Breart G, Jonville AP, Courcier S, Lassale C,GoehrsJM 197 Cc Autret E, Jonville AP, Dutertre JP, Bertiere E MC, Robert M, Averous M,Couet W 83 Calvo R, Suarez E, Aguilera L, Rodriguez AverousM— AutretE 83 SasiainJM 484 Eadie MJ >BernusI 473 CandianiC > MiadonnaA 127 Ebihara A—SudohT 267 Capdeville R, Mousson B, Bax G, Bertrand Y, Eckernis S-A-—>GrahnénA 143 B Philippe N 385 Eckrich B > Volz-ZangC 399 Carlsson M > Bjérkman§ 325 Edwards M—Imbimbo BP 421 Backman JT, Aranko K, Himberg J-J, Olkkola Carlsson MS, Denneberg T, Emanuelsson Eggen AE, AndrewM 491 KT 551 B-M, Kagedal B, LindgrenS 576 Ehrsson H, Wallin I, Ros AM, Eksborg S, Berg Bailleul F >BertinP 3 Carrara V, Porchet H, Dayer P 29 M 375 Balant LP AaronsL 389 CarucciP—>BrunoA 411 Eichelbaum M—BotschS 133 Baldo-EnziG — Zambon§ 221 Cassader M—BrunoA 411 EksborgS —EhrssonH 375 Barbhaiya RH. Shukla UA, Pfeffer M, Cavallo-PerinP—BrunoA 411 E] Desoky E-Gramatté T 253 Pittman KA, Shrotriya R, Laroudie C, CawelloW —KnaufH 9 Emanuelsson B-M > Carlsson MS_ 576 GammansRE 41 Cawello W, Schweer H, Miiller R, Bonn R, Encarnacion M, ChinI 533 BardJM—HagenE 445 SeyberthHW 275 EnlundH >NiskanenL 101 Bartelink ML, Wollersheim H, Vemer H, Chang FY,ChenF,LeeSD 91 ErdegB—KirstenR 271 Thomas CMG, Boo T de, Thien T 557 ChenF—ChangFY 91 Eriksen H-M—HagenE 445 BartucciF >ConciaE 371 Chetty M, Miller R, MoodleySV 523 Eriksson JW, Fowelin J, Urbanavicius V BascoLK—GimenezF 561 ChiandussiL > VeglioF 119 469 Bax G—Capdeville R 385 ChinI > EncarnacionM 533 Erkelens DW > TonstadS 405 Beaulac-Baillargeon L,RocheleauS 451 Chossegros P—>Combarnous F 379 Bégaud B—MiremontG 285 Clark GA Newnham DM 511 Behne M, Bremerich D, Heinrich J, Claus M— WolterK 179 F Schumacher H,SchererM 301 Combarnous F, Fouque D, Bernard N, Belz GG —MeyCde 295 Boulieu R, Chossegros P, Laville M, Zech P Falkenhausen M von—ReichelC 417 Berg M—EhrssonH 375 379 FarehS—NonyP 191 Bergogne-Bérézin E, Muller-Serieys C, Concia E, Cruciani M, Bartucci F, Arrigoni L, FarinottiR ~GimenezF 561 Aubier M, Dombret MC 87 LongoniA 371 FerroniMA -PacificiGM 49 Berings D, Blondeel L, HabrakenH 501 CortellaA—Zambon$ 221 Fleishaker JC, Hulst LK 35 Bernard N->Combarnous F 379 CottiniM—MiadonnaA 127 Fliser D> Neubeck M 537 Berntorp E> Bjérkman$ 325 Couet W—> AutretE 83 Fliser D > ZwettlerU 185 Bernus I, Dickinson RG, Hooper WD, Eadie Couraud L— Mignot A 383 Fliser M—Neubeck M 537 MJ 473 CourcierS— AutretE 197 Fouque D->CombarnousF 379 Bertiere MC AutretE 83 CrepaldiG— ZambonS 221 Fowelin J > ErikssonJW 469 Bertin P, Lapicque F, Payan E, Rigaud M, CrucianiM—ConciaE 371 Fowles SE, Pratt SK, Laroche J, Prince WT Bailleul F, Jaeger S, Treves R, NetterP 3 Currie D— McDevitt DG 23 355 Fritschka Fritschka E> Wolter K 179 J Laroche J—>FowlesSE 355 Fruchart JC HagenE 445 Laroudie C—BarbhaiyaRH 41 Fujimura A—>SudohT 267 Jackson SHD >GainsboroughN 163 LassaleC— AutretE 197 JaegerS—BertinP 3 LaufenH—ZimmermannT 147 Jahn P > Volz-ZangC 399 Laville M—>Combarnous F 379 G JaéhnchenE—RufG 545 Le Bras J >GimenezF 561 JahnchenE—VogtD 319 Leaver N— Tsang VT 261 Gainsborough N, Nelson ML, Maskrey V, Jensen JD, Jensen LW, Madsen JK 333 LeeSD—ChangFY 91 Swift CG, JacksonSHD 163 Jensen LW—JensenJD 333 Leeuwenkamp OR, Visscher HW, Mensink Gammans RE > BarbhaiyaRH 41 Jerling M, AlvanG 67 CK,JonkmanJHG 243 GaoHY,LiWanPoA 71 Jibikil, YamaguchiN, MomonoiF 367 Leizorovicz ANonyP 191 GeraS—>RufG 545 JohanssonG —GrahnénA 143 Lenaerts V—Imbimbo BP 421 GillotinC —GimenezF 561 Johnston A Tsang VT 261 Li Wan Po A—GaoHY 71 Gimenez F, Gillotin C, Basco LK, Bouchaud Jonkman JHG > Leeuwenkamp OR Li Wan Po A— Zhang WY 517 O, Aubry A-F, Wainer IW, Le Bras J, 243 Liebmann B— Ding RW 455 FarinottiR 561 Jonville AP— AutretE 83,197 Lievre M—NonyP 191 GirreC > RochdiM 351 Jormanainen V >NiskanenL 101 Liliemark J > AlbertioniF 563 Giuliani L > PacificiGM 49 Joubert M— Mignot A 383 Lindgren S Carlsson MS 576 Giverhaug T > KlemetsdalB 231 Juliusson G > AlbertioniF 563 Lipworth BJ >Newnham DM 511 GoehrsJM—AutretE 197 LithellHRenelandR 431 Golay A Tonstad$ 405 Lizamore DJ >SnymanJR 19 Gordin A—KeranenT 151 K LofflerK > RufG 545 Gozdzik A — Orzechowska-Juzwenko K 481 LongoniA—ConciaE 371 Grahnén A, Olsson B, Johansson G, Eckernas KadoyaC Domino EF 527 Louton T, Kuhnz W, Dibbelt L, Knuppen R S-A 143 Kagedal B-> Carlsson MS 576 77 Gramatté T, El Desoky E, Klotz U 253 KailaT—AlihankaJ 507 Léwenhielm CGP > MalmvikJ 291 GrudenG—BrunoA 411 Kaila T, Roivas L, Neuvonen PJ 237 LuusHG-—RufG 545 Gucci A > PacificiGM 49 Kales A Vgontzas AN 209 Kallio A > Kivist6 KT 345 Kamali F, ThomasSHL 565 M H KarloécaiK > TomesanyiJ 173 KarlssonM —KeranenT 151 MacGregor IR Wright RA 279 HabrakenH—BeringsD 501 Karonen S-L > Mattila MJ 215 MadsenJK —-JensenJD 333 Hagen E, Istad H, Ose L, Bodd E, Eriksen Karsenty H > Lacarelle B 477 Malmvik J, Lowenhielm CGP, Melander A H-M, Selvig V, Bard JM, Fruchart JC, Borge Kaufmann J > Krause W 339 291 M, Wolf M-C, Pfister P 445 Keller U + Miserez AR 107 Mant T—Imbimbo BP 421 HaenniA—RenelandR 431 Kerdanen T, Gordin A, Karlsson M, Korpela K, ManzatoE—ZambonS$ 221 HaradaK—SudohT 267 Pentikainen PJ, Rita H, Schultz E, Seppala Maskrey V >GainsboroughN 163 HaramburuF + MiremontG 285 L, WikbergT 151 Matsuoka S ~ Domino EF 527 Hasegawa T, Takagi K, Nadai M, Ogura Y, Kirsten R, Breidert M, Nelson K, Heine A, Mattila MJ, VanakoskiJ, Mattila-Evenden NabeshimaT 55 Rosenkranz S, Erdeg B, Niebch G, Borbe ME, KaronenS-L 215 Haugh MC>NonyP 191 HO, Siebert-Weigel M, Respondek J 271 Mattila-Evenden ME > Mattila MJ 215 Heine A KirstenR 271 Kivist6 KT, Kallio A, Neuvonen PJ 345 McDevitt DG ~Newnham DM 511 HeinkeleG—BotschS 133 Klemetsdal B, Straume B, Giverhaug T, McDevitt DG, Currie D, Nicholson AN, HeinrichJ >BehneM 301 AarbakkeJ 231 Wright NA, Zetlein MB 23 Heritier F Tsang VT 261 Klotz U>GramattéT 253 McFarlane LC > Newnham DM 511 Herngren L— AlbertioniF 563 Knauf H, Cawello W, Schmidt G, Mutschler E Meese CO BotschS 133 Hilsted J> Hvidberg A 15 9 Melander A > MalmvikJ 291 Himberg J-J > Backman JT 551 Knuppen R—LoutonT 77 Melander A—MerloJ 393 HimbergJ- J > LaaksonenR 313 KochHJ 573 MelchioR— VeglioF 119 Hodson ME > Tsang VT 261 Konishi H, Morita K, Yamaji A 309 Mensink CK ~ Leeuwenkamp OR 243 Hoffmann A > Merkel U 175 KorpelaK —KeranenT 151 Mentré F> AaronsL 389 Holland RL, Wesnes K, DietrichB 461 Krause W, Schuhmann-Giampieri G, Staks T, Merkel U, Sigusch H, Hoffmann A 175 Hommes FDM > Broek Lvanden 225 KaufmannJ 339 Merlo J, Ranstam J, Rastam L, Wessling A, Hooper WD > BernusI 473 Kroemer HK >BotschS 133 MelanderA 393 Hora Z > Orzechowska-Juzwenko K Kubota K, Inman WHW 497 Mey C de, Breithaupt K, Seibert-Grafe M, 481 Kuhnz W > LoutonT 77 BelzGG 295 Horriere F > Lacarelle B 477 Miadonna A, Cottini M, Candiani C, Tedeschi Hulst LK >FleishakerJC 35 A 127 Hvidberg A, Djurup R, HilstedJ 15 L Mignot A, Millerioux L, Couraud L, Durgeat S,Joubert M 383 Laaksonen R, Ojala J-P, Tikkanen MJ, Milejski P > Orzechowska-JuzwenkoK 481 HimbergJ-J 313 Miller R->ChettyM 523 Lacarelle B, Blin O, Audebert C, Auquier P, Millerioux L— Mignot A 383 Imbimbo BP, Mant T, Edwards M, Amin D, Karsenty H, Horriere F, Durand A 477 Miremont G, Haramburu F, Bégaud B, Péré Dalton N, Boutignon F, Lenaerts V, Lacey LF >DixonJS 167 JC,DangoumauJ 285 Wiithrich P, DeghenghiR 421 Lahdenperé A —AlihankaJ 507 Miserez AR, Ross RA, Keller U 107 Inman W, Pearce G, WiltonL 115 Lahiri A Sridhara BS 427 MoccettiT —TonstadS 405 Inman WHW -> Kubota K 497 Lange RDahlqvistR 1 MomonoiF — Jibikil 367 Istad H-HagenE 445 Langley SJ >DixonJS 167 Moodley SV Chetty M 523 Lapicque F >BertinP 3 Morelli MC > PacificiGM 49 Laporte J-R—AgustiA 95 Morita K > KonishiH 309 Uusitupa Morita K, Yamaji A 137 PearceG—InmanW 115 SchulzW—RufG 545 MorselliPL— AaronsL 389 Pentikadinen PJ >KerainenT 151 Schumacher H +BehneM 301 Mousson B > Capdeville R 385 Péré JC MiremontG 285 SchwartzJ I Van HeckenA 123 Muller-Serieys C > Bergogne-Bérézin E Perrie AM—WrightRA 279 Schweer H > CawelloW 275 87 Persson CGA > SvenssonC 59 Seibert-Grafe M—»>MeyCde 295 Miiller R->CawelloW 275 PfaffG— ZimmermannT 147 Selvig V-—HagenE 445 MutschlerE— Ding RW 455 Pfeffer M— BarbhaiyaRH 41 Seppala L—KerainenT 151 MutschlerE—KnaufH 9 Pfister P—> HagenE 445 Seyberth HW > Cawello W 275 Mutschler E—Neubeck M 537 Philippe N > Capdeville R 385 Shiga T-—SudohT 267 Myers DC Vgontzas AN 209 Pierce DM—AllenA 159 Shrotriya R->BarbhaiyaRH 41 Pipkorn U >SvenssonC 59 Shukla UA > BarbhaiyaRH 41 Pittman KA > BarbhaiyaRH 41 Siebert-Weigel M— Kirsten R 271 N PomettaD ->TonstadS 405 Sigusch H Merkel U 175 Porchet H Carrara V 29 Sj6str6m PA 575 Nabeshima T > Hasegawa T 55 Port RE—DingRW 455 Snyman JR—SommersK De 441,569 NadaiM—HasegawaT 55 Pratt SK — FowlesSE 355 SnymanJR—WykMvan 437 Nelson K > KirstenR 271 Prince WT > Fowles SE 355 Snyman JR, De Sommers K, Wyk M van, Nelson ML—GainsboroughN 163 Pritsch M—Neubeck M 537 Lizamore DJ 19 NetterP—BertinP 3 Proost JH > Broek Lvanden 225 Sowunmi A —AhanekuJE 249 Neubeck M, Fliser D, Pritsch M, WeiBer K, Spahn-Langguth H Ding RW 455 Fliser M, Nussberger J, Ritz E, Mutschler E Sridhara BS, Thomas P, Lahiri A, Raftery EB 537 R 427 Neuvonen PJ > KailaT 237 Staks T-— Krause W 339 Neuvonen PJ > Kivist6 KT 345 Rabbia F > VeglioF 119 Stappaerts I, Van Schil L, Van der Veken J Newnham DM, Wheeldon NM, McFarlane Raftery EB >Sridhara BS 427 305 LC, Clark GA, McDevitt DG, Lipworth BJ RanstamJ—MerloJ 393 Steimer J-L— AaronsL 389 511 RastamL—MerloJ 393 Stenhouse F > Wright RA 279 Ng HWK, Walley TJ, Tsao Y, Breckenridge Reichel C, Falkenhausen M von, Brockmeier Straume B > KlemetsdalB 231 AM 361 D,DenglerHJ 417 SudrezE—CalvoR 484 NgJ— Van HeckenA 123 ReitsmaJ—TonstadS 405 Sudoh T, Fujimura A, Shiga T, Sasaki M, Nicholson AN McDevitt DG 23 Reneland R, Andersson P-E, Haenni A, Harada K, Tateishi T, Ohashi K, Ebihara A Niebch G > KirstenR 271 LithellH 431 267 Niewinski P — Orzechowska-Juzwenko K Respondek J > Kirsten R 271 Svensson C, Alkner U, Pipkorn U, Persson 481 ReyNdela—RufG 545 CGA 59 Niskanen L, Enlund H, Jormanainen V, Rhodes KM, BrownSN 479 Swiebodzki L — Orzechowska-Juzwenko K Nissinen A, UusitupaM 101 Riemersma RA > Wright RA 279 481 Nissinen A—NiskanenL 101 RigaudM-—BertinP 3 Swift CG + GainsboroughN 163 Nony P, Boissel J-P, Lievre M, Leizorovicz A, Rimoy GH, Wright DM, Bhaskar NK, Rubin Haugh MC, FarehS, Breyne Bde 191 PC 203 NowickiM > ZwettlerU 185 RitaH —>KeranenT 151 T Nussberger J > Neubeck M 537 Ritz E—NeubeckM 537 Ritz E—ZwettlerU 185 Takagi K > HasegawaT 55 Robert M—>AutretE 83 TateishiT ~SudohT 267 oO Rochdi M, Sabouraud A, Girre C, Venet R, TaylorGO—AhanekuJE 249 ScherrmannJM 351 Tedeschi A MiadonnaA 127 Ogbuokiri JE, Ozumba BC, Okonkwo PO Rocheleau S > Beaulac-BaillargeonL 451 Temellini A > PacificiGM 49 89 Rodriguez SasiainJM—CalvoR 484 Thien T > Bartelink ML 557 Ogura Y — HasegawaT 55 Rogstad B 487 Thomas CMG —> Bartelink ML 557 OhashiK —SudohT 267 Roivas L— KailaT 237 Thomas P —Sridhara BS 427 Ojala J-P ~LaaksonenR 313 Ros AM—>EhrssonH 375 Thomas SHL > KamaliF 565 Okonkwo PO > Ogbuokiri JE 89 RosenkranzS—KirstenR 271 Tikkanen MJ >LaaksonenR 313 OlivettiC—BrunoA 411 Ross RA —Miserez AR 107 Tjandramaga TB > Van Hecken A 123 Olkkola KT > Backman JT 551 Rowland M— AaronsL 389 TomesanyiJ, KarlécaiK 173 Olsson B-—GrahnénA 143 Rubin PC Rimoy GH 203 Tonstad S, Pometta D, Erkelens DW, Ose L, Ortmann K— Ding RW 455 Ruf G, Gera S, Luus HG, Trenk D, Rey N de Moccetti T, Schouten JA, Golay A, Reitsma Orzechowska-Juzwenko K, Pawlik J, la, Loffler K, Schulz W, JahnchenE 545 J, Del Bufalo A, Pasotti E, Wal P van der Niewinski P, Milejski P, Dembowski J, Turek 405 J, Gozdzik A, SwiebodzkiL,HoraZ 481 Toon S$ —DixonJS 167 Ose L—HagenE 445 S Trenk D—RufG 545 Ose L—TonstadS 405 Trenk D> VogtD 319 Ozumba BC > OgbuokiriJE 89 Sabouraud A—RochdiM 351 TrevesR—BertinP 3 Salako LA —AhanekuJE 249 Tsang VT, Johnston A, Heritier F, Leaver N, SartoreG—ZambonS 221 Hodson ME, YacoubM 261 P SasakiM—SudohT 267 Tsao YNgHWK 361 SchererM—BehneM 301 Turek J ->Orzechowska-JuzwenkoK 481 Pacifici GM, Ferroni MA, Temellini A, Gucci Scherrmann JM —RochdiM 351 A, Morelli MC, GiulianiL 49 Schmidt G—KnaufH 9 PaganoG—BrunoA 411 Schneidrowski B > Volz-ZangC 399 U Palm D > Volz-ZangC 399 SchoutenJA—TonstadS 405 PasottiE—TonstadS 405 Schuhmann-GiampieriG > Krause W 339 UpwardJ—AllenA 159 Pawlik J ~ Orzechowska-JuzwenkoK 481 Schulte B > Volz-ZangC 399 Urbanavicius V > ErikssonJW 469 PayanE-—BertinP 3 Schultz E—KeranenT 151 Uusitupa M > NiskanenL 101 Van der Veken Vv WalkerO—AhanekuJE 249 Wyk M van, De Sommers K, Snyman JR Walley TJ >NgHWK 361 437 Van der Veken J > StappaertsI 305 WallinI —EhrssonH 375 Van Hecken A, Depré M, SchwartJzI , Weber E—DingRW 455 Tjandramaga TB, Winchell GA, De WeiBer K >Neubeck M 537 Y Lepeleire I, Ng, De Schepper PJ J 123 Wesnes K—>HollandRL 461 Van Schil L > StappaertsI 305 Wessling A—MerloJ 393 YacoubM > Tsang VT 261 Vanakoski J — Mattila MJ 215 Wheeldon NM—>NewnhamDM 511 Yamaguchi N > Jibikil 367 Veglio F, Rabbia F, Melchio R, Chiandussi L Wierda JMKH —> Broek L van den Yamaji A—KonishiH 309 119 WikbergT—KeranenT 151 Yamaji A MoritaK 137 Vemer H - Bartelink ML 557 Wildfeuer A— ZimmermannT 147 YeatesRA—ZimmermannT 147 Venet R-RochdiM 351 WiltonL—InmanW 115 Vgontzas AN, Kales A, Bixler EO, Myers DC Winchell GA > Van Hecken A 123 209 Wolf M-C-—>HagenE 445 Z Visscher HW + Leeuwenkamp OR 243 Wollersheim H > Bartelink ML Vogt D, Trenk D, Bonn R,J ahnchenE 319 557 Zambon §, Cortella A, Sartore G, Baldo-Enzi Volz-Zang C, Eckrich B,J ahn P, Wolter K, Claus M, FritschkaE 179 G, ManzatoE,CrepaldiG 221 Schneidrowski B, Schulte B, Palm D 399 Wright DM > Rimoy GH_ 203 Zech P >CombarnousF 379 VozehS$— AaronsL 389 Wright NA >McDevittDG 23 Zetlein MB >McDevittDG 23 Wright RA, Perrie AM, Stenhouse F, Alberti Zhang WY, LiWanPoA 517 KGMM, Riemersma RA, MacGregor IR, Zimmermann T, Yeates RA, Laufen H, Pfaff Ww BoonNA 279 G, Wildfeuer A 147 Wiithrich P—Imbimbo BP 421 Zussman BD > AllenA 159 Wainer IW >GimenezF 561 WykMvan—SnymanJR 19 Zwettler U, Fliser D, Nowicki M, Ritz E WalP vander—TonstadS 405 WykM van—SommersK De 441,569 185 Doxycycline Subject Index Budesonide; liver, man, sulphotransferase, testosterone, drug me- tabolism 49 (S = Supplement) Buspirone; pharmacokinetics, renal impairment, hepatic impair- ment, healthy volunteers 41 Cc The key words given at the end of the summary of each article have been classified as primary and Candidiasis, Fluconazole; prescription-event, monitoring, safety in secondary key words separated by a semicolon. In pregnancy 115 the index the primary key words are listed alphabeti- Capsaicin, Cough, Captopril; glycopyrrolate 437 cally; the individual primary key words are permuted Capsaicin, Diabetic neuropathy; pain relief, patients 517 in such way that each of them appears in first place Captopril, Capsaicin, Cough; glycopyrrolate 437 once. The secondary key words follow the primary Captopril, Central effects, Atenolol; short term administration, healthy volunteers 23 ones without permutation. Cefotiam, Tissue distribution; cephalosporin, lung tissue 383 Central effects, Atenolol, Captopril; short term administration, healthy volunteers 23 Cetirizine; cutaneous hypersensitivity reaction, eosinophil re- A sponse, grass pollen allergy, blister fluid 19 2-Chloro-2’-deoxyadenosine (CdA), Protein binding, Cladribine; pharmacokinetics, leukaemia 563 ACE Inhibition, Renal failure, Perindoprilat; potassium, extra- Chlorpromazine, Schizophrenic patients; population pharmacoki- renal disposal, renal excretion, hyperkalaemia 185 netics, clearance, cigarette smoking, cannabis smoking 523 Acetaminophen, Ibuprofen, Fever; children, infections disease, ad- Ciclotropium; heart rate, pharmacokinetic/pharmacodynamic verse effects 197 modelling, effect compartment 455 Adverse drug reaction, Prescription-event monitoring; post- Cimetidine, Gastric ulcer, Helicobacter pylori; smoking 91 marketing surveillance, terminology 497 Cladribine, 2-Chloro-2’-deoxyadenosine (CdA), Protein binding; Adverse drug reaction; causality assessment, agreement 285 pharmacokinetics, leukaemia 563 Allergic rhinitis, N-acetyl-aspartyl-glutamate; histamine, leuko- Clotiazepam, Schizophrenia; benzodiazepine derivative, auditory triene C,, nasal challenge 127 hallucinations 367 Allopurinol, Famciclovir, Herpes; pharmacokinetics interaction, Codeine, Drug-prescription; combination analgesics, pharmaco- xanthine oxidase 355 epidemiology, sex-factor, aged 491 Alprazolam, Psychomotor performance, Fluvoxamine; metabolic Coenzyme Q, Ubiquinonen; lovastatin, simvastatin, long-term inhibition, sedation, drug interaction, serotonin reuptake inhibi- treatment 313 tor, benzodiazepine 35 Colchicine; pharmacokinetics, healthy volunteers, elderly subjects, Amiloride, Insulin sensitivity; hyperinsulinaemic euglycaemic absolute bioavailability 351 clamp, glucose utilization, glucose production, healthy volun- teers 469 Combined hyperlipidaemia, Pravastatin; LDL, cholesterol, trigly- Amlodipine, Hypertension; blood pressure, blood biochemistry, cerides, adverse effects, LDL size 221 COMT, Genetic polymorphism; pharmacogenetics, ethnic varia- haematology, Africans 249 tion, Norway, Saami people 231 Amoxycillin, Flucloxacillin, Digoxin; penicillin V, penicillin anti- Congestive heart failure, Theophylline; periodic breathing, adeno- biotics 479 sine 173 Antidepressants, Suicide; risk differences, amitriptyline, lofepra- Cough, Captopril, Capsaicin; glycopyrrolate 437 mine, trimipramine 291 Coumarin, Flavonoids, Grapefruit juice; pharmacokinetics, cyto- Anti-emetic, Granisetron; pharmacokinetics, tolerance, ascending chrome P450, metabolism inhibition 175 dose, healthy subjects 159 Cyciosporin, Cystic fibrosis; pharmacokinetics 261 Arithmetic mean, Standard deviation; pharmacokinetics 573 Cyclosporine A; uptake, human erythrocytes, HPLC 417 Asthma, Pemirolast; theophylline, drug interaction, pharmacoki- Cystic fibrosis, Cyclosporin; pharmacokinetics 261 netics 55 Atenolol, Captopril, Central effects; short term administration, healthy volunteers 23 a,-Acid glycoprotein, Epilepsy; anticonvulsant, carbamazepine, D phenytoin, phenobarbital, valproate, y-glutamyl transpeptidase, Depression, Serotonin; central 5-hydroxytryptamine, fluoxetine, enzyme induction, seizure control 137 f,-Adrenoceptor antagonist, Esmolol; tricresylphosphate, phar- dexfenfluramine, prolactin release 441 Dexmedetomidine; transdermal, pharmacokinetics, «-adrenocep- macokinetics, effect kinetics 399 tor agonist 345 Diabetes mellitus; Type 2 (non-insulin-dependent) diabetes melli- tus, antidiabetic drugs, therapeutic traditions, questionnaire sur- B vey 101 Diabetic neuropathy, Capsaicin; pain relief, patients 517 Bemetizide, Salt excretion pattern; Na*, K*, Cl, Mg”*, Ca*, chron- Diazoxide, Tenoxicam; diastolic pressure, glucose, insulin 569 ic renal failure, renal haemodynamics 9 Digoxin, Amoxycillin, Flucloxacillin; penicillin V, penicillin anti- Benzodiazepines, General Practice; industry-independent drug in- biotics 479 formation, prescribing, intervention, primary care 501 Diltiazem, Hypertension; intra-arterial blood pressure 427 Bioequivalence, Fluocinolone acetonide; drug formulations, vaso- Diltiazem; immediate-release tablet, controlled-release tablet, constrictor activity, topical steroids, tristimulus colour analysis, steady state, pharmacokinetics 243 corticosteroids 71 Dose adjustment, Lisinopril; ACE inhibitors, pharmacokinetics, Bronchodilatation, Oxitropium bromide; nebulised solution, dose- pharmacodynamics, renal failure 537 response study, chronic obstructive pulmonary disease, anti- Doxycycline; bioavailability, pH dependent absorption, pharmaco- cholinergic bronchodilator, adverse effects 305 kinetics, carrageenate, adverse events 143 Vil Drug development Drug development, Population approach; software, pharmaco- G kinetics, pharmacodynamics 389 Drug utilisation, Standardisation; defined daily dose (DDD), car- Ganciclovir, Renal failure; pharmacokinetics, haemodialysis 379 diovascular data, age 393 Gastric ulcer, Helicobacter pylori, Cimetidine; smoking 91 Drug utilization, Myocardial infarction; secondary prevention, B- General Practice, Benzodiazepines; industry-independent drug in- adrenoceptor antagonists, acetylsalicylic acid, calcium channel formation, prescribing, intervention, primary care 501 blockers 95 Genetic polymorphism, COMT; pharmacogenetics, ethnic varia- Drug-prescription, Codeine; combination analgesics, pharmaco- tion, Norway, Saami people 231 epidemiology, sex-factor, aged 491 Glucagon, Hypoglycaemia; intranasal, glucose appearance rate 1 Granisetron, Anti-emetic; pharmacokinetics, tolerance, ascending dose, healthy subjects 159 E Grapefruit juice, Coumarin, Flavonoids; pharmacokinetics, cyto- chrome P450, metabolism inhivition 175 Enantiomers, Malaria, Halofantrine; stereoselectivity, Plasmo- Growth hormone, Hexarelin; growth hormone releasing peptides dium falciparum 561 421 Enoxacin, Theophylline, Fluconazole; cytochrome P-4501 A, drug metabolism, drug interaction 309 Entacapone; catechol-O-methyltransferase; pharmacokinetics; H healthy volunteers, adverse effects, metabolism 151 Enuresis, Oxybutynine chloride; children, pharmacokinetics, ad- Haemophilia B, Factor IX; macromolecules, pharmacokinetics, verse effects, anticholinergic actions 83 methodological study 325 Epanolol, Ischaemic heart disease, Metoprolol; tissue-type plasmi- Halofantrine, Enantiomers, Malaria; stereoselectivity, Plasmo- nogen activator, plasminogen activator inhibitor type 1 279 dium falciparum 561 Epilepsy, a,-Acid glycoprotein; anticonvulsant, carbamazepine, Halothane, Protein binding; drug interaction 484 phenytoin, phenobarbital, valproate, y-glutamy] transpeptidase, Helicobacter pylori, Cimetidine, Gastric ulcer; smoking 91 enzyme induction, seizure control 137 Herpes, Allopurinol, Famciclovir; pharmacokinetics interaction, Erythropoietin; recombinant human erythropoietin, pharmacoki- xanthine oxidase 355 netics, subcutaneous, absorption, bioavailability 333 Hexarelin, Growth hormone; growth hormone releasing peptides Esmolol, 6 ,-Adrenoceptor antagonist; tricresylphosphate, phar- 421 macokinetics, effect kinetics 399 Hoffmann reflex, Tobacco smoking; recovery cycle, plasma nico- Ethinyl estradiol, Trapezoidal rule; variance components, pharma- tine, plasma cotinine 527 cokinetics 77 Hydrocortisone, Methylprednisolone, Insulin resistance; glucose metabolism 411 Hypercholesterolaemia, Fluvastatin; cholestyramine, drug treat- F ment of hypercholesterolaemia, LDL cholesterol, HDL choles- terol, triglycerides, Lp(a), apolipoproteins 445 Factor IX, Haemophilia B; macromolecules, pharmacokinetics, Hypercholesterolaemia, Simvastatin; low density lipoprotein, high methodological study 325 density lipoprotein, triglycerides, HMG-CoA-reductase inhibi- Famciclovir, Herpes, Allopurinol; pharmacokinetics interaction, tors, adverse effects 107 xanthine oxidase 355 Hyperlipidaemia, Orlistat; lipase inhibitor, fat malabsorption, Females, Raynaud’s phenomenon, Skin perfusion; cooling test, cu- LDL cholesterol 405 taneous blood flow, sex hormones, vasospasm 557 Hypertension, Amlodipine; blood pressure, blood biochemistry, Fever, Acetaminophen, Ibuprofen; children, infections disease, ad- haematology, Africans 249 verse effects 197 Hypertension, Diltiazem; intra-arterial blood pressure 427 Flavonoids, Grapefruit juice, Coumarin; pharmacokinetics, cyto- Hypertension, Fosinopril; essential, insulin sensitivity, carry-over chrome P450, metabolism inhibition 175 effect, angiotensin converting enzyme inhibition, atenolol 431 Flosequinan, Xamoterol; pharmacodynamic interactions, healthy Hypertension, Lisinopril, Nifedipine; multicentre study 487 volunteers 361 Hypoglycaemia, Glucagon; intranasal, glucose appearance rate Flucloxacillin, Digoxin, Amoxycillin; penicillin V, penicillin anti- 15 biotics 479 Fluconazole, Candidiasis; prescription-event, monitoring, safety in pregnancy 115 Fluconazole, Enoxacin, Theophylline; cytochrome P-4501 A, drug Ibuprofen, Fever, Acetaminophen; children, infections disease, ad- metabolism, drug interaction 309 verse effects 197 Fluconazole, Itraconazole; pharmacokinetics, food interaction, Infusion, Prostaglandin E,; pharmacokinetics, metabolism, volun- gastric emptying time, pH radiocapsule 147 teers 275 Fluocinolone acetonide, Bioequivalence; drug formulations, vaso- Insomnia, Temazepam; elderly, efficacy, tolerance, intermittent ad- constrictor activity, topical steroids, tristimulus colour analysis, ministration 209 corticosteroids 71 Insulin resistance, Hydrocortisone, Methylprednisolone; glucose Fluvastatin, Hypercholesterolaemia; cholestyramine, drug treat- metabolism 411 ment of hypercholesterolaemia, LDL cholesterol, HDL choles- Insulin sensitivity, Amiloride; hyperinsulinaemic euglycaemic terol, triglycerides, Lp(a), apolipoproteins 445 clamp, glucose utilization, glucose production, healthy volun- Fluvoxamine, Alprazolam, Psychomotor performance; metabolic teers 469 inhibition, sedation, drug interaction, serotonin reuptake inhibi- Intestinal absorption, Ranitidine; intestinal perfusion, second tor, benzodiazepine 35 peak, intestinal water flux, absorption gradient 253 Fosinopril, Hypertension; essential, insulin sensitivity, carry-over Iopromide; X-ray contrast medium, pharmacokinetics, tolerability, effect, angiotensin converting enzyme inhibition, atenolol 431 healthy volunteers, adverse effects 339 Fourier, Isradipine; rhythm, hypertension, diurnal blood pressure rhythm 119 Ischaemic heart disease, Metoprolol, Epanolol; tissue-type plasminogen activator, plasminogen activator inhibitor type1 279 Renal failure Isosorbide dinitrate, Pirsidomine; CAS 936, EDRF, dorsal hand oO vein 295 Isosorbide dinitrate; route of administration, isosorbide-5-mononi- Opiates, Mr 2264 Cl, Respiratory depression; ventilation, mor- trate, finger pulse wave, pharmacokinetics, haemodynamic ef- phine, analgesics, tolerability, adverse events 301 fects, plasma nitrates 319 Opioid antagonist, U-62066E; blood pressure, heart rate, plasma Isradipine, Fourier; rhythm, hypertension, diurnal blood pressure catecholamines, naloxone, Doppler regional blood flow, kappa rhythm 119 receptor 203 Israpidine; haemodynamics, pharmacokinetics, healthy volunteers, Org 7617, Neuromuscular blockade; dose-response relation, time drug input rate 29 course of action, adverse effects, non-depolarizing 225 Itraconazole, Fluconazole; pharmacokinetics, food interaction, Orlistat, Hyperlipidaemia; lipase inhibitor, fat malabsorption, gastric emptying time, pH radiocapsule 147 LDL cholesterol 405 Ivermectin, Breast milk 89 Oxitropium bromide, Bronchodilatation; nebulised solution, dose- response study, chronic obstructive pulmonary disease, anti- cholinergic bronchodilator, adverse effects 305 L Oxybutynine chloride, Enuresis; children, pharmacokinetics, ad- verse effects, anticholinergic actions 83 Lisinopril, Dose adjustment; ACE inhibitors, pharmacokinetics, pharmacodynamics, renal failure 537 P Lisinopril, Nifedipine, Hypertension; multicentre study 487 Paracetamol, Pregnancy; pharmacokinetics 451 Pemirolast, Asthma; theophylline, drug interaction, pharmacoki- M netics 55 Perindoprilat, ACE Inhibition, Renal failure; potassium, extra- Malaria, Halofantrine, Enantiomers; stereoselectivity, Plasmo- renal disposal, renal excretion, hyperkalaemia 185 dium falciparum 561 Phenobarbitone; phenobarbitone-N -glucoside, urine, metabolism Medifoxamine; pharmacokinetics, pharmacodynamics, elderly 473 volunteers 163 Phenytoin, Saliva; therapeutic drug monitoring, pharmacokinetics 5-Methoxypsoralen, Psoriasis; food, pharmacokinetics 375 565 Meropenem, Respiratory infections; bronchial secretions, local Phosphodiesterase inhibitors, Mortality; meta-analysis, chronic concentrations 87 heart failure, vasodilator 191 6-Mercaptopurine, Thiopurine-methyl-transferase; acute lympho- Piretanide, Ramipril; pharmacokinetics, pharmacodynamics, heal- blastic leukaemia; interaction 385 thy volunteers 545 Methylprednisolone, Insulin resistance, Hydrocortisone; glucose Pirsidomine, Isosorbide dinitrate; CAS 936, EDRF, dorsal hand metabolism 411 vein 295 Metoprolol, Epanolol, Ischaemic heart disease; tissue-type plasmi- Plasma exudation, Xanthine derivatives, Nasal airways; fibrinogen, nogen activator, plasminogen activator inhibitor type 1 279 bradykinins, terbutaline, theophylline, nasal mucosa, nasal lav- Metoprolol; bioavailability, bioequivalence, receptor binding as- age, histamine provocation test 59 say, pharmacokinetics, sustained release formulation 237 Population approach, Drug development; software, pharmacoki- Midazolam, Roxithromycin; drug interaction, pharmacokinetics netics, pharmacodynamics 389 551 Pravastatin, Combined hyperlipidaemia; LDL, cholesterol, trigly- Mortality, Phosphodiesterase inhibitors; meta-analysis, chronic cerides, adverse effects, LDL size 221 heart failure, vasodilator 191 Pregnancy, Paracetamol; pharmacokinetics 451 Mr 2264 Cl, Respiratory depression, Opiates; ventilation, mor- Prescription-event monitoring, Adverse drug reaction; postmar- phine, analgesics, tolerability, adverse events 301 keting surveillance, terminology 497 Mucosal oral therapeutic system, Nystatin; candidiasis, nystatin Propafenone, Sparteine; glucuronides, CYP2D6 phenotype 133 salivary concentrations 533 Prostaglandin E,, Infusion; pharmacokinetics, metabolism, volun- Myocardial infarction, Drug utilization; secondary prevention, f- teers 275 adrenoceptor antagonists, acetylsalicylic acid, calcium channel Protein binding, Cladribine, 2-Chloro-2’-deoxyadenosine (CdA); blockers 95 pharmacokinetics, leukaemia 563 Protein binding, Halothane; drug interaction 484 Psoriasis, 5-Methoxypsoralen; food, pharmacokinetics 375 N Psychomotor performance, Fluvoxamine, Alprazolam; metabolic inhibition, sedation, drug interaction, serotonin reuptake inhibi- N-acetyl-aspartyl-glutamate, Allergic rhinitis; histamine, leuko- tor, benzodiazepine 35 triene C,, nasal challenge 127 Psychomotor performance, Suriclone; zopiclone, chlorpromazine Naftopidil, Serotonin; platelets, aggregation 271 interaction, memory, prolactin, adverse effects 215 Naproxen, Synovial fluid, Rheumatoid arthritis; NSAIDs, eicosa- noid, concentration/effect 3 R Nasal airways, Plasma exudation, Xanthine derivatives; fibrinogen, bradykinins, terbuialine, theophylline, nasal mucosa, nasal lav- Ramipril, Piretanide; pharmacokinetics, pharmacodynamics, heal- age, histamine provocation test 59 thy volunteers 545 Neuromuscular blockade, Org 7617; dose-response relation, time Ranitidine, Intestinal absorption; intestinal perfusion, second course of action, adverse effects, non-depolarizing 225 peak, intestinal water flux, absorption gradient 253 Nifedipine, Hypertension, Lisinopril; multicentre study 487 Nortriptyline; dose-dependent kinetics, therapeutic drug monitor- Ranitidine, Renal impairment; pharmacokinetics 167 Raynaud’s phenomenon, Skin perfusion, Females; cooling test, ing 67 cutaneous blood flow, sex hormones, vasospasm 557 Nystatin, Mucosal oral therapeutic system; candidiasis, nystatin salivary concentrations 533 Renal clearance; pharmacokinetics 575 Renal failure, Ganciclovir; pharmacokinetics, haemodialysis 379 Renal failure, Perindoprilat, ACE Inhibition; potassium, extra- renal disposal, renal excretion, hyperkalaemia 185 Renal impairment Renal impairment, Ranitidine; pharmacokinetics 167 T Respiratory depression, Opiates, Mr 2264 Cl; ventilation, mor- phine, analgesics, tolerability, adverse events 301 Teicoplanin; haemodialysis, renal failure, pharmacokinetics 179 Respiratory infections, Meropenem; bronchial secretions, local Temazepam, Insomnia; elderly, efficacy, tolerance, intermittent ad- concentrations 87 ministration 209 Rheumatoid arthritis, Naproxen, Synovial fluid; NSAIDs, eicosa- Tenoxicam, Diazoxide; diastolic pressure, glucose, insulin 569 noid, concentration/effect 3 Testosterone metabolism, Steroid 5a-reductase inhibitor; MK- Roxithromycin, Midazolam; drug interaction, pharmacokinetics 0434, pharmacodynamics, pharmacokinetics 123 551 Theophylline, Congestive heart failure; periodic breathing, adeno- sine 173 Theophylline, Fluconazole, Enoxacin; cytochrome P-4501 A, drug S metabolism, drug interaction 309 Theophylline; flumequine, drug interaction, pharmacokinetics Salbutamol; male, female, 8, -adrenoceptor, menstrual cycle, sys- 477 temic responses 511 Thiopurine-methyl-transferase, 6-Mercaptopurine; acute lympho- Saliva, Phenytoin; therapeutic drug monitoring, pharmacokinetics blastic leukaemia; interaction 385 565 Tissue distribution, Cefotiam; cephalosporin, lung tissue 383 Salmon calcitonin, Skin blister fluid concentration; synthetic, plas- Tobacco smoking, Hoffmann reflex; recovery cycle, plasma nico- ma concentration, pharmacokinetics, adverse effects 371 tine, plasma cotinine 527 Salt excretion pattern, Bemetizide; Na*, K*, Cl, Mg”*, Ca’*, chron- Trapezoidal rule, Ethinyl estradiol; variance components, pharma- ic renal failure, renal haemodynamics 9 cokinetics 77 Schizophrenia, Clotiazepam; benzodiazepine derivative, auditory hallucinations 367 Schizophrenic patients, Chlorpromazine; population pharmacoki- U netics, clearance, cigarette smoking, cannabis smoking 523 Scopolamine, Sleep; transdermal, autonomic nervous activity 507 U-62066E, Opioid antagonist; blood pressure, heart rate, plasma Serotonin, Depression; central 5-hydroxytryptamine, fluoxetine, catecholamines, naloxone, Doppler regional blood flow, kappa dexfenfluramine, prolactin release 441 receptor 203 Serotonin, Naftopidil; platelets, aggregation 271 Ubiquinonen, Coenzyme Q; lovastatin, simvastatin, long-term Simvastatin, Hypercholesterolaemia; low density lipoprotein, high treatment 313 density lipoprotein, triglycerides, HMG-CoA-reductase inhibi- Umespirone; buspirone, EEG, cognitive, neuroendocrine effect tors, adverse effects 107 461 Skin blister fluid concentration, Salmon calcitonin; synthetic, plas- ma concentration, pharmacokinetics, adverse effects 371 Skin perfusion, Females, Raynaud’s phenomenon; cooling test, cu- x taneous blood flow, sex hormones, vasospasm 557 Sleep, Scopolamine; transdermal, autonomic nervous activity 507 Sparteine oxidation polymorphism, Poland 481 Xamoterol, Flosequinan; pharmacodynamic interactions, healthy Sparteine, Propafenone; glucuronides, CYP2D6 phenotype 133 volunteers 361 Standard deviation, Arithmetic mean; pharmacokinetics 573 Xanthine derivatives, Nasal airways, Plasma exudation; fibrinogen, Standardisation, Drug utilisation; defined daily dose (DDD), car- bradykinins, terbutaline, theophylline, nasal mucosa, nasal lav- diovascular data, age 393 age, histamine provocation test 59 Steroid 5a-reductase inhibitor, Testosterone metabolism; MK- 0434, pharmacodynamics, pharmacokinetics 123 Suicide, Antidepressants; risk differences, amitriptyline, lofepra- mine, trimipramine 291 Suriclone, Psychomotor performance; zopiclone, chlorpromazine interaction, memory, prolactin, adverse effects 215 Synovial fluid, Rheumatoid arthritis, Naproxen; NSAIDs, eicosa- noid, concentration/effect 3 >

See more

The list of books you might like

Upgrade Premium
Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.
DMCA & Copyright: Dear all, most of the website is community built, users are uploading hundred of books everyday, which makes really hard for us to identify copyrighted material, please contact us if you want any material removed.
Copyright @ PDFdrive.to, 2022 | We love our users